Modulation of ASC-derived extracellular vesicles containing cargo that specifically enhances wound healing.

IF 4.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Frontiers in Pharmacology Pub Date : 2025-09-15 eCollection Date: 2025-01-01 DOI:10.3389/fphar.2025.1635151
Jodi P Gurney, John W Ludlow, Michael J Van Kanegan, Robin L Smith
{"title":"Modulation of ASC-derived extracellular vesicles containing cargo that specifically enhances wound healing.","authors":"Jodi P Gurney, John W Ludlow, Michael J Van Kanegan, Robin L Smith","doi":"10.3389/fphar.2025.1635151","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>We have developed a bioreactor-based production system for manufacturing Human Adipose Stromal Cell (ASC) extracellular vesicles (EVs), which includes exosomes, using a highly controlled and tunable environment that can modify the cargo of these nanovesicles. The patented innovation focuses on engineering novel pro-healing EVs with therapeutic activity and using a topical formulation to treat diabetic ulcers.</p><p><strong>Methods: </strong>To evaluate biological activity of tuned ASC EVs, functional activity assays were performed using human primary dermal fibroblast and keratinocyte culture models. Molecular and biochemical assays were used to assess cytokine regulation, collagen production and cell migration. Rodent wound healing models were used to assess therapeutic potential of modified exosomes. A Human volunteer case study was carried out with a consenting individual suffering from chronic diabetic ulcers.</p><p><strong>Results: </strong>Herein we demonstrate that our proprietary engineered ASC EVs, eXo<sup>3</sup> exosomes, contain a unique activity profile that reduces inflammatory cytokines, stimulates collagen production, as well as activates keratinocyte and fibroblast proliferation and migration. When formulated with an emollient and topically applied to an <i>in vivo</i> excisional wound model, tuned eXo<sup>3</sup> exosomes demonstrated enhanced wound closure, increased keratinization, collagen deposition, and overall improved recover rate. In a clinical case study addressing non-healing diabetic foot ulcers, conducted under informed consent, topical treatment with tuned eXo<sup>3</sup> exosomes formulated in a proprietary gel serum showed complete wound closure and dermal regeneration.</p><p><strong>Conclusion: </strong>Our current research efforts have developed an EV manufacturing system that can be directed to improve the healing capacity of ASC-derived EVs. We show enhanced wound healing and repair activity <i>in vitro</i> and <i>in vivo</i>. Our data supports the regenerative properties of exosomes and reinforces their strong therapeutic potential.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1635151"},"PeriodicalIF":4.8000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477913/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2025.1635151","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: We have developed a bioreactor-based production system for manufacturing Human Adipose Stromal Cell (ASC) extracellular vesicles (EVs), which includes exosomes, using a highly controlled and tunable environment that can modify the cargo of these nanovesicles. The patented innovation focuses on engineering novel pro-healing EVs with therapeutic activity and using a topical formulation to treat diabetic ulcers.

Methods: To evaluate biological activity of tuned ASC EVs, functional activity assays were performed using human primary dermal fibroblast and keratinocyte culture models. Molecular and biochemical assays were used to assess cytokine regulation, collagen production and cell migration. Rodent wound healing models were used to assess therapeutic potential of modified exosomes. A Human volunteer case study was carried out with a consenting individual suffering from chronic diabetic ulcers.

Results: Herein we demonstrate that our proprietary engineered ASC EVs, eXo3 exosomes, contain a unique activity profile that reduces inflammatory cytokines, stimulates collagen production, as well as activates keratinocyte and fibroblast proliferation and migration. When formulated with an emollient and topically applied to an in vivo excisional wound model, tuned eXo3 exosomes demonstrated enhanced wound closure, increased keratinization, collagen deposition, and overall improved recover rate. In a clinical case study addressing non-healing diabetic foot ulcers, conducted under informed consent, topical treatment with tuned eXo3 exosomes formulated in a proprietary gel serum showed complete wound closure and dermal regeneration.

Conclusion: Our current research efforts have developed an EV manufacturing system that can be directed to improve the healing capacity of ASC-derived EVs. We show enhanced wound healing and repair activity in vitro and in vivo. Our data supports the regenerative properties of exosomes and reinforces their strong therapeutic potential.

调节asc衍生的细胞外囊泡,其中含有特异性促进伤口愈合的货物。
我们开发了一种基于生物反应器的生产系统,用于制造人类脂肪基质细胞(ASC)细胞外囊泡(ev),其中包括外泌体,使用高度可控和可调的环境,可以修改这些纳米囊泡的货物。这项专利创新专注于具有治疗活性的工程新型促愈合电动汽车,并使用局部配方治疗糖尿病溃疡。方法:利用人原代真皮成纤维细胞和角化细胞培养模型进行功能活性测定,以评价调整后的ASC ev的生物活性。采用分子和生化分析来评估细胞因子的调节、胶原蛋白的产生和细胞迁移。采用啮齿动物伤口愈合模型来评估修饰外泌体的治疗潜力。一项人类志愿者案例研究是与一个同意患有慢性糖尿病溃疡的个体一起进行的。结果:在这里,我们证明了我们专有的工程ASC ev, eXo3外泌体,含有一种独特的活性谱,可以减少炎症细胞因子,刺激胶原蛋白的产生,并激活角化细胞和成纤维细胞的增殖和迁移。当与润肤剂一起配制并局部应用于体内切除伤口模型时,调整的eXo3外泌体显示出增强伤口闭合,增加角化,胶原沉积和整体恢复率。在一项针对未愈合的糖尿病足溃疡的临床病例研究中,在知情同意的情况下进行,用专有凝胶血清配制的调节eXo3外泌体局部治疗显示伤口完全愈合和皮肤再生。结论:我们目前的研究工作已经开发出一种电动汽车制造系统,可以直接提高asc衍生电动汽车的愈合能力。我们在体外和体内都显示了增强的伤口愈合和修复活性。我们的数据支持外泌体的再生特性,并加强了它们强大的治疗潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Pharmacology
Frontiers in Pharmacology PHARMACOLOGY & PHARMACY-
CiteScore
7.80
自引率
8.90%
发文量
5163
审稿时长
14 weeks
期刊介绍: Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信